Long
OpGen Long - Possible FDA approval soon
Updated
OpGen has gone through a complete accumulation cycle in anticipation of FDA approval for their AMR gene panel. During the last few days of broad market pull back, we see above average volume the downside holding support at $2.80 - $2.90. RSI on the 1HR is approaching oversold. SP has fallen through 50EMA we could possibly see a correction back to uptrend support. 1HR resistance around $3.20 $3.50 $4.00 $4.50 $4.80
Recent Corporate Overview published on 2/16/21
Google - "wyckoff accumulation schematic 1" for more information on accumulation cycle
Recent Corporate Overview published on 2/16/21
Google - "wyckoff accumulation schematic 1" for more information on accumulation cycle
Trade active
Current average $2.937Point and Figure chart has bullish price objective of $6.25
Note
Recent news 3/1 - receives regulatory approval of the Curetis Unyvero System as an in vitro diagnostics ((IVD)) instrument system in China.
3/2 - Analysts raise price target to $7.00
Note
Posted update in comments by accident. Also to add, 3.1M new warrants issued to the previous holder at an exercise price of $3.56
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.